(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 7.73%
@ $82.68
Utstedt: 14 feb 2024 @ 15:30
Avkastning: -14.91%
Forrige signal: feb 12 - 18:22
Forrige signal:
Avkastning: -0.71 %
Live Chart Being Loaded With Signals
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial...
Stats | |
---|---|
Dagens volum | 331 890 |
Gjennomsnittsvolum | 492 690 |
Markedsverdi | 4.51B |
EPS | $0 ( 2024-03-21 ) |
Neste inntjeningsdato | ( $-0.670 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -32.42 |
ATR14 | $0.100 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-02 | Miller Deborah Ann | Sell | 3 000 | Stock Option (Right to Buy) |
2024-05-02 | Miller Deborah Ann | Buy | 3 000 | Class A Common Stock |
2024-05-02 | Miller Deborah Ann | Sell | 1 566 | Class A Common Stock |
2024-05-02 | Miller Deborah Ann | Sell | 1 296 | Class A Common Stock |
2024-05-02 | Miller Deborah Ann | Sell | 138 | Class A Common Stock |
INSIDER POWER |
---|
-40.04 |
Last 100 transactions |
Buy: 779 479 | Sell: 1 683 589 |
Volum Korrelasjon
Nuvalent, Inc. Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
HURC | 0.845 |
BIMI | 0.84 |
CRBU | 0.837 |
AMRS | 0.836 |
GRPN | 0.833 |
SPRB | 0.832 |
WRAP | 0.827 |
ASUR | 0.821 |
LMST | 0.819 |
CHB | 0.818 |
10 Mest negative korrelasjoner | |
---|---|
PAAS | -0.871 |
RING | -0.859 |
EH | -0.854 |
HSON | -0.837 |
SABRP | -0.832 |
AMRK | -0.826 |
ALR | -0.822 |
DYAI | -0.82 |
LWAY | -0.812 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Nuvalent, Inc. Korrelasjon - Valuta/Råvare
Nuvalent, Inc. Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-1.480 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.